Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04280718 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx.
- Active
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT04280718: Active Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx.
NCT04280718 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) that is active but no longer recruiting, run by argenx. The registered enrollment target is 229 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04280718, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod PH20 SC
Study Locations (20)
Florida
- Investigator site 0010072 - Boca Raton
- Investigator site 0010144 - Coral Springs
- Investigator site 0010023 - Jacksonville
- Investigator site 0010068 - Maitland
- Investigator site 0010059 - Miami
- Investigator site 0010006 - Tampa
California
- Investigator site 0010032 - Carlsbad
- Investigator site 10190 - Pomona
- Investigator site 0010160 - Rancho Mirage
- Investigator site 0010071 - San Francisco
Arizona
- Investigator site 0010013 - Phoenix
- Investigator site 0010055 - Scottsdale
Alabama
- Investigator site 0010065 - Birmingham
Colorado
- Investigator site 0010057 - Centennial
Iowa
- Investigator site 0010011 - Iowa City
Kansas
- Investigator site 0010015 - Fairway
Kentucky
- Investigator site 10147 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What the registry record for NCT04280718 still lists
NCT04280718 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.
NCT04280718 names 20 study sites across 11 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04280718 about?
NCT04280718 is a clinical study titled "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)". This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to exp...
What is the current status of trial NCT04280718?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2020-09-18. Estimated completion is 2027-04-30.
What conditions does trial NCT04280718 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What interventions are being tested in trial NCT04280718?
The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04280718?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04280718 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04280718's enrollment target sits among peer trials
229 264th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
COMPLETED · Phase 2
-
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI